Kazia Therapeutics (KZIA) Accounts Payables (2017 - 2025)

Kazia Therapeutics (KZIA) has disclosed Accounts Payables for 5 consecutive years, with $6.5 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Accounts Payables fell 34.75% year-over-year to $6.5 million, compared with a TTM value of $6.5 million through Jun 2025, down 34.75%, and an annual FY2025 reading of $6.6 million, down 33.64% over the prior year.
  • Accounts Payables was $6.5 million for Q2 2025 at Kazia Therapeutics, down from $9.9 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $9.9 million in Q2 2024 and bottomed at $2.7 million in Q2 2022.
  • Average Accounts Payables over 3 years is $6.4 million, with a median of $6.5 million recorded in 2025.
  • Peak annual rise in Accounts Payables hit 34.75% in 2025, while the deepest fall reached 34.75% in 2025.
  • Year by year, Accounts Payables stood at $2.7 million in 2022, then skyrocketed by 268.79% to $9.9 million in 2024, then plummeted by 34.75% to $6.5 million in 2025.
  • Business Quant data shows Accounts Payables for KZIA at $6.5 million in Q2 2025, $9.9 million in Q2 2024, and $2.7 million in Q2 2022.